Vorolanib (X-82), an oral anti-VEGFR/PDGFR/CSF1R tyrosine kinase inhibitor, with everolimus in solid tumors: results of a phase I study.
Invest New Drugs
; 39(5): 1298-1305, 2021 10.
Article
in En
| MEDLINE
| ID: mdl-33738668
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pyrroles
/
Pyrrolidines
/
Protein Kinase Inhibitors
/
Everolimus
/
Indoles
/
Neoplasms
Limits:
Adult
/
Aged
/
Aged80
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Invest New Drugs
Year:
2021
Document type:
Article
Affiliation country:
Country of publication: